Lottery.com and Sports.com Power Triple Driver Lineup at Detroit Grand Prix
Ilott, Foster, and Murray Fly the Flag for Global Brands Across IndyCar and Indy NXT
DETROIT, May 30, 2025 (GLOBE NEWSWIRE) -- Lottery.com Inc. (Nasdaq: LTRY, LTRYW)('the Company' or 'Lottery.com') and Sports.com, the next-generation sports media platform, are proud to announce their continued sponsorship of three exceptionally talented drivers — Callum Ilott, Louis Foster and Sebastian Murray — as they take to the streets of Detroit this weekend in both the NTT INDYCAR SERIES and INDY NXT by Firestone.
Callum Ilott: Lottery.com Helmet Deal Extended Through 2025Following his standout showing at the Indianapolis 500, Callum Ilott will now wear the Lottery.com logo front and center on his custom helmet for the remainder of the 2025 season. Driving car number 90 for the Prema racing team, Ilott represents Lottery.com's lead entry in the top-tier INDYCAR SERIES.
'We're proud to extend our relationship with Callum,' . 'I had the pleasure of spending time with Callum at the Indy 500 following his great drive, and I was really impressed not only by his ability to drive the wheels off a car, but also by his commercial understanding of how important partnerships like this are for the future. We look forward to working with Callum through this year and beyond.'
Louis Foster: Sports.com Partnership Continues Post-Indy 500After finishing 12th and earning Top Rookie Honors at the Indy 500 last weekend, Louis Foster continues his strong run in the Rahal Letterman Lanigan Racing No. 45 car. The Sports.com branding will now appear on the chin of Foster's car, showcasing the Company's commitment to elite racing talent.
'Detroit's a tricky track and there have been some eventful races there in recent years,' 'The main goal is to qualify well and stay out of trouble to keep our momentum going.'
'It's just, like, super bumpy,' . 'It's really short and narrow. For us to be on the limit and not end up in the wall, it just makes it very, very challenging. In some areas, it's very narrow. In others, you have different tarmacs in different corners, which makes it hard to feel the grip of the car.'
'Not only did Louis deliver one of the outstanding drives of the Indy 500 weekend,' , 'but having spent time with him personally, I can say he's got a fantastic personality — every sponsor's dream. He has a great racing pedigree. He's the complete package.'
Sebastian Murray: Rising Star Continues Indy NXT JourneyIn the INDY NXT by Firestone championship, Sebastian Murray will once again carry Lottery.com branding on the rear spoiler and nose wing endplates of his Andretti Cape Motorsports machine. As the youngest driver in the group, Murray's progression symbolizes the long-term vision for both Lottery.com and Sports.com in supporting emerging motorsport talent and driver development.
'Sebastian represents the future,' . 'He's calm under pressure and has the talent to rise quickly through the ranks. We're excited to watch his journey unfold and to be a part of it.'
'Marc and I also had the pleasure of spending time with Sebastian over the Indy 500 weekend,' , 'and he's not only a charming young man but an exceptional natural driver. There's no doubt he's one to watch.'
Detroit Street Circuit: The Challenge AheadDetroit's circuit is one of the most demanding in motorsport, with tight corners, changing surfaces, and limited overtaking zones that test both driver skill and race strategy. This marks the fourth major event in May, closing out the busiest month of the INDYCAR calendar.
Broadcast Schedule (ET):
Fri, May 30 – Practice 1: 3:00 PM (FS2, Sky Sports F1 UK)
Sat, May 31 – Practice 2: 9:00 AM / Qualifying: 12:00 PM (FS1, Sky Sports)
Sun, June 1 – Warm-Up: 9:30 AM / Race: 12:30 PM (FOX, Sky Sports F1 UK)
Triple Sponsorship, One Global VisionThis three-driver lineup exemplifies Lottery.com and Sports.com's investment in world-class motorsport to raise global brand awareness and fan engagement. From helmet design to car decals, the brands are front and center on one of the most watched racing series in the world.
'This is more than sponsorship — it's the start of a movement,' . 'We're building long-term equity in the sports and entertainment verticals, and these partnerships are already delivering global brand recognition along with signaling to our shareholders that we are making strides to increase the value of our premium brand assets.'
About Lottery.com
The Lottery.com Inc. (NASDAQ: LTRY, LTRYW) family of brands — including Sports.com, Tinbu and WinTogether, comprise a unified ecosystem that integrates gaming, entertainment, and sports. Follow the Company on X, Instagram and Facebook.
For more information, please visit www.lottery.com or www.sports.com or contact our media relations team.
Important Notice Regarding Forward-Looking Statements
This press release contains statements that constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company's strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words 'could,' 'should,' 'will,' 'may,' 'believe,' 'anticipate,' 'intend,' 'estimate,' 'expect,' 'project,' 'initiatives,' 'continue,' the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company's internal accounting controls, additional examination of the preliminary conclusions of such review, the Company's ability to secure additional capital resources, the Company's ability to continue as a going concern, the Company's ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company's ability to regain compliance with the Bid Price Requirement, the Company's ability to regain compliance with Nasdaq Listing Rules, the Company's ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading 'Risk Factors' in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC's website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/19dde0b9-86b4-4956-802f-8f1ec3fe1ab0
https://www.globenewswire.com/NewsRoom/AttachmentNg/6f7ef34f-55a7-4558-9225-72e72363a259
This press release was published by a CLEAR® Verified individual.
CONTACT: For more information, please visit www.lottery.com or www.sports.com or contact our media relations team at press@lottery.com.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
28 minutes ago
- Indianapolis Star
Colton Herta's wish after qualifying pole? An 'easy race with no yellows' at Detroit Grand Prix
DETROIT — After a six-race start to his 2025 IndyCar season full of "what ifs" on race days and close calls on Saturdays, Colton Herta will finally have the best seat in the house to take the green flag for Sunday's Detroit Grand Prix, with hopes of turning his first pole of his season and 15th of his career into his first win of 2025, too. The Andretti Global driver finished well over a tenth of a second ahead of A.J. Foyt Racing's David Malukas in the battle for pole Sunday, having had four Fast 6 appearances already this year but so far no poles, matching his pole performance a year ago on the 1.645-mile downtown Detroit street course. But in the chaos of last year's race that featured eight cautions and 47 of 100 laps ran under yellow, Herta and the No. 26 Andretti Global crew faltered and fell back to 19th. Entering IndyCar's third race since the series' shift to the downtown street course track, Andretti Global and others are looking to knock Chip Ganassi Racing off the top step, with Alex Palou (2023) and Scott Dixon (2024) taking wins on the course thus far. 'We've been close a few times this year making it on a pole run, so I'm happy to do that and start P1 tomorrow,' said Herta, who's looking for his first podium finish of 2025. Entering Sunday, the Andretti Global driver's best finish of fourth came at The Thermal Club. Outside that, he's finished 16th at St. Pete after starting second, seventh at Long Beach after starting second and seventh at Barber after qualifying third, along with dismal runs during the Month of May at IMS (25th on the IMS road course and 14th in the Indy 500). Entering Sunday, Herta sits ninth in points, 22 back of eighth-place Will Power, 36 back of his fifth-place teammate Kyle Kirkwood, 74 back of second-place Pato O'Ward and 186 of runaway championship leader Alex Palou. 'Now we just need a nice, easy race with no yellows,' said Herta, referencing IndyCar's run of three full races (and parts of two others) that ran without a single caution earlier in the season. Among a Fast 6 that included Kirkwood, Christian Lundgaard, Palou, Malukas and Graham Rahal, the battle for pole was essentially between the pair of Andretti Global teammates and Malukas, all three of whom had only used one set of Firestone alternate tires during Round 1 of qualifying instead of two like so many of their competitors had — done so they could better ensure they'd advance to the Fast 12. Despite ending up tying his best starting spot of his IndyCar career in second, Malukas said he and his No. 4 squad expected to have a better shot at giving Andretti a serious run, but finished well back of Herta on their fastest laps (1:00.4779 vs. 1:00.6492). Kirkwood, too, felt he gave away an opportunity for his second pole of 2025, having been sitting four-tenths up on Herta's fastest lap with half a lap left before making enough wall contact to break a tow link that left him losing time in bunches on the final couple corners. Entering Sunday, Kirkwood is the only driver to have finished ahead of Palou in the two-time defending series champ's only non-win of the year at Long Beach, where the Chip Ganassi Racing driver still managed a runner-up finish. 'I've never been more disappointed with third in my life,' said Kirkwood, who was stripped earlier this week of his sixth-place Indy 500 finish due to a post-race tech inspection failure. 'But congrats to Colton. I'm glad one of us got (pole), because it would've been really frustrating if neither one of us got it. 'I know I just threw away a pole, without a doubt, but our cars are fast, and that's what's really important. And I see no reason why we won't be fast once again (on Sunday).' Starting fourth on Sunday, Lundgaard said after stepping out of his car he was proud to have finished as the fastest driver not to have used a new set of alternates in the Fast 6, as he looks to potentially overtake teammate O'Ward for second in points and with any luck chip away a bit at his 125-point gap to Palou. Meanwhile, Palou, who finished 15th-fastest in Practice 1 Friday afternoon, was more than happy to settle for sixth in the Fast 6 after a whirlwind 48-hour media tour in New York City following his first career Indy 500 win on Sunday. In his five wins so far in 2025, Palou has started eighth (St. Pete), third (Thermal), pole (Barber and IMS road course) and sixth (Indy 500). He'll start fifth Sunday, with Graham Rahal dropping back from fifth to 11th due to a six-spot grid penalty for an unapproved engine change.
Business Wire
29 minutes ago
- Business Wire
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. 'The data presented today from the PANOVA-3 trial of Tumor Treating Fields show a clinically meaningful and statistically significant improvement in overall survival for people with locally advanced pancreatic cancer,' said Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial. 'Importantly, we also saw an extension in the duration of time before pain progressed. Pain is a hallmark of this disease, and as a clinician, the potential of this therapy to address this aspect of pancreatic cancer is very encouraging. These results illustrate the potential of Tumor Treating Fields therapy concomitant with gemcitabine and nab-paclitaxel to become a standard of care for unresectable, locally advanced pancreatic cancer.' The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclitaxel alone. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) for patients treated with TTFields. 'The encouraging data from the Phase 3 PANOVA-3 study demonstrate a meaningful improvement in outcomes for patients with unresectable, locally advanced pancreatic cancer—including pain reduction and a statistically significant improvement in overall survival,' said Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. 'Pancreatic cancer remains one of the most challenging cancers to treat globally, with approximately 134,000 new cases diagnosed annually in China alone. Zai Lab participated in this trial and looks forward to continuing our collaboration with Novocure to bring this innovative therapy to patients in China as quickly as possible.' 'Most people with pancreatic cancer are diagnosed with advanced disease, which is very difficult to treat and only about 1 in 10 people are alive five years after diagnosis,' said Nicolas Leupin, MD, PhD, Chief Medical Officer, Novocure. 'The results shared today at ASCO and in the Journal of Clinical Oncology demonstrate that Tumor Treating Fields therapy improved overall survival and pain-free survival in unresectable, locally advanced pancreatic cancer. We plan to submit these data to the FDA in the second half of 2025 to support a premarket approval for Tumor Treating Fields therapy.' Results from PANOVA-3 In the intent-to-treat population, patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel had an mOS of 16.2 months compared to 14.2 months for patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement [hazard ratio (HR) 0.82; p=0.039 (N=571)]. TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints including the one-year survival rate and pain-free survival. Pancreatic cancer can cause significant pain as the disease progresses and managing pain is a key clinical challenge. The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group with 68.1% [95% CI: 62.0–73.5] compared to those who received gemcitabine and nab-paclitaxel alone, 60.2% [95% CI: 54.2–65.7], p=0.029. Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months [95% CI: 10.3–22.8] compared to a median 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone [95% CI: 7.4–12.7]; HR 0.74 [95% CI: 0.56–0.97], p=0.027. This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until an increase of 20 or more points was reported by patients on a visual scale for pain or until death. Quality of life was also measured as a secondary endpoint. Analyses were performed for all patients using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with the pancreatic cancer specific PAN26 addendum. Deterioration-free survival in global health status, pain and digestive problems were significantly improved in patients receiving TTFields therapy concomitant with gemcitabine and nab-paclitaxel compared to the gemcitabine and nab-paclitaxel alone group. Full analysis of the quality of life results in PANOVA-3 will be shared at a future scientific conference. There was no statistically significant difference in additional secondary outcome measures of progression-free survival, local progression-free survival, objective response rate, puncture-free survival or tumor resectability rate between the TTFields with gemcitabine and nab-paclitaxel and the gemcitabine and nab-paclitaxel arms. TTFields therapy was well-tolerated, no new safety signals were observed, and safety was consistent with prior clinical studies. Mild to moderate skin adverse events (AEs) were the most common device-related AEs. Data Presentation & Publication Details The PANOVA-3 data, (LBA 3500) Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC), will be presented today by Dr. Picozzi in Hall D1 during the 3:00 – 6:00 p.m. Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary oral session. The Phase 3 PANOVA-3 publication in the Journal of Clinical Oncology, Tumor Treating Fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase 3 PANOVA-3 study, will be available online at Novocure Investor Event Novocure will host an investor event featuring Dr. Picozzi and Novocure leadership after the oral presentation. Event details and a link to a live webcast of the event are available on the investor relations page of For more information or to request in-person attendance, please contact Novocure investor relations at investorinfo@ Regulatory & Ongoing Clinical Study of TTFields for Pancreatic Cancer Novocure plans to file for regulatory approval for use of TTFields therapy in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3 in the U.S. in the second half of 2025. The company also plans to file for regulatory approval in EU, Japan and other key markets. Novocure continues to follow patients in its Phase 2 PANOVA-4 trial exploring the use of TTFields therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. PANOVA-4 has completed enrollment with data anticipated in the first half of 2026. About PANOVA-3 PANOVA-3 is an international prospective, randomized, open-label, controlled Phase 3 clinical trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields) therapy used concomitantly with gemcitabine and nab-paclitaxel, as a first-line treatment for locally advanced pancreatic adenocarcinoma. Patients were randomized to receive either TTFields therapy concomitant with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity. The PANOVA-3 trial enrolled 571 patients who were randomized 1:1 and followed for a minimum of 18 months. About PANOVA-4 PANOVA-4 is an international, multi-center, Phase 2 clinical trial designed to test the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. The primary endpoint is disease control rate. Secondary endpoints include overall survival, progression-free survival, one-year survival rate, objective response rate, progression-free survival at six months, duration of response, and toxicity. The study is designed to enroll 76 patients and enrollment is complete. About Pancreatic Cancer in China Pancreatic cancer is one of the most common and deadliest cancers globally. In China, there were an estimated 134,374 new cases in 2022, and it is now the eighth most common cancer type 1. The current median survival of patients with locally advanced, unresectable pancreatic cancer is nine to twelve months, and the five-year survival rate was 7.2% 2, making it the malignancy with the lowest survival rate in China. 1 Xia C, Dong X, Li H et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022; 135: 584-590. 2 Hu JX, Zhao CF, Chen WB et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol 2021; 27: 4298-4321. About Tumor Treating Fields Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit About Zai Lab Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer. Novocure's global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit and follow @Novocure on LinkedIn and Twitter. Zai Lab Forward-Looking Statements This press release contains forward-looking statements about future expectations, plans, and prospects for Zai Lab, including, without limitation, statements regarding the prospects of and plans for developing and commercializing TTFields therapy, the potential benefits of TTFields therapy, and the potential treatment of pancreatic cancer. These forward-looking statements may contain words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would,' and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and the SEC's website at
Yahoo
32 minutes ago
- Yahoo
Tempus AI hits back at scathing short report
Tempus AI hits back at scathing short report originally appeared on TheStreet. On May 28, Tempus AI () stock plunged as the market reacted to a damning report from short seller Spruce Point Capital. One day later, the company responded to the accusations against it. A company at the intersection of healthcare and artificial intelligence (AI), Tempus began trading on the Nasdaq in June 2024, a year that didn't see too many high-profile initial public offerings (IPOs). For that reason, Tempus stood out, and investors were hungry for new AI stocks to buy. 💵💰💰💵 While trading has been fairly volatile, TEM stock has mostly risen and is currently up 35% for the year. Since 2025 began, its performance has been quite strong, with year-to-date (YTD) gains of almost 60%. The damning short report from Spruce Point Capital pushed shares down this week, although TEM stock has since recovered. Tempus took the opportunity to respond to short sellers' claims and offer its own take on the allegations. Since its founding in 2009, Spruce Point Capital has released over 100 forensic short reports, laying out cases against companies across various industries. In April 2025, it revealed short positions in travel tech company Clear Secure and popular beverage producer Monster recently, though, it published a detailed short report that revealed a bet against Tempus stock. In it, the short-seller estimated that TEM stock posed a '50%-60% potential long-term downside and market underperformance risk' for investors, primarily due to concerns regarding its leadership and AI capabilities. For context, Tempus uses AI to improve precision medicine solutions, as well as drug discovery and diagnostics. Its operating system is reported to analyze medical information and make it accessible for patients, as well as doctors and scientific researchers. However, Spruce Point's researchers make it clear in the report that they harbor grave concerns about the AI hype surrounding TEM stock, suggesting that it may be significantly overblown. 'Our concerns about the Company's AI capabilities deepened after we evaluated split-second product demonstrations from promotional videos and screenshots from the Company's website,' the report states. 'Apparently, Tempus has not properly figured out how to leverage AI to cross reference and check even basic facts such as patient age and the sequencing order of samples and deliveries.' The short seller also discusses Tempus founder and CEO Eric Lefkofsky, highlighting comparisons he has drawn to his company and market leaders such as Tesla and Nvidia. 'He suggests that Tempus is likely to reach a similar inflection point, and that vast upside is around the corner. However, 10 years since being founded in 2015, there is no evidence that Tempus has generated a profit or net positive cash flow,' Spruce Point notes. More AI News: OpenAI teams up with legendary Apple exec Major AI CEO sounds alarm on jobless 'bloodbath' in near-term Salesforce makes a big bet on booming tech market The report raises the point that after a decade of operation, both Tesla and Nvidia had posted $2 billion in revenue and achieved at least one cash flow positive year. It notes that in 2024, only $12.4 million, roughly 2% of Tempus's yearly revenue, came from AI applications. The underlying theme of the Spruce Point short report seems to be that it believes Tempus's AI hype is overblown and poses a massive risk for investors. For that reason, TEM stock earns a Strong Sell Opinion from the all companies respond after being targeted by a short seller, but on May 29, Tempus issued a statement on X, addressing the report. The company described Spruce Point's claims as inaccurate and misleading, encouraging investors to do their own research. 'We do not intend to respond through the media to a report that is riddled with inaccuracies, conjecture, and ill-informed hypotheticals,' the health care company stated. 'It also fails to address Tempus' history of strong financial performance and impressive growth.' Tempus also took its argument a step further, claiming that the last five stocks targeted by Spruce Point are up 'on average, over 20% in the past 4 months.' The company added that it stands by its results and remains committed to helping health care professionals leverage AI for the benefit of AI hits back at scathing short report first appeared on TheStreet on May 31, 2025 This story was originally reported by TheStreet on May 31, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
